Jun 01,2021

Non-invasive wearables for remote monitoring of HbA1c and glucose variability: proof of concept

Introduction Diabetes prevalence continues to grow and there remains a significant diagnostic gap in one-third of the US population that has pre-diabetes. Innovative, practical strategies to improve monitoring of glycemic health are desperately needed. In this proof-of-concept study, we explore the relationship between non-invasive wearables and glycemic metrics and demonstrate the feasibility of using non-invasive wearables to estimate glycemic metrics, including hemoglobin A1c (HbA1c) and glucose variability metrics.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 07,2021

An Examination of the Glucose Management Indicator in Young Children with Type 1 Diabetes

Previous studies utilizing glucose data from continuous glucose monitors (CGM) to estimate the Glucose Management Indicator (GMI) have not included young children or determined appropriate GMI formulas for young children with type 1 diabetes (T1D).

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 10,2021

Examining Sensor Agreement in Neural Network Blood Glucose Prediction

Successful measurements of interstitial glucose are a key component in providing effective care for patients with diabetes. Recently, there has been significant interest in using neural networks to forecast future glucose values from interstitial measurements collected by continuous glucose monitors (CGMs). While prediction accuracy continues to improve, in this work we investigated the effect of physiological sensor location on neural network blood glucose forecasting.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 11,2021

Accuracy of CGM Systems During Continuous and Interval Exercise in Adults with Type 1 Diabetes

Continuous glucose monitoring systems (CGMs) play an important role in the management of T1D, but their accuracy may reduce during rapid glucose excursions. The aim of study was to assess the accuracy of recent rt-CGMs available in Italy, in subjects with T1D during 2 sessions of physical activity: moderate continuous (CON) and interval exercise (IE).

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 11,2021

Accuracy and Stability of a Subcutaneous Flash Glucose Monitoring System in Critically Ill Patients

Flash glucose monitoring (FGM) systems can reduce glycemic variability and facilitate blood glucose management within the target range. However, in critically ill patients, only small (n < 30) studies have examined the accuracy of FGM and none have assessed the stability of FGM accuracy. We evaluated the accuracy and stability of FGM in critically ill patients.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 25,2021

LATE-BREAKING DATA DEMONSTRATE ABBOTT'S FREESTYLE® LIBRE SYSTEM SUPPORTS HEALTH EQUITY FOR MILLIONS OF AMERICANS LIVING WITH DIABETES

Comparative data presented at the American Diabetes Association J19 Scientific Sessions show Abbott's diabetes technology delivers the same reductions of HbA1c and acute complications(1,2) as the competitor systems while reaching a much wider, more diverse population

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 27,2021

Tandem Diabetes Care Announces Presentations Demonstrating Positive Real-World Improvements with Control-IQ Technology Across Diverse Populations

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, today presented positive real-world data from ongoing use of the t:slim X2™ insulin pump with Control-IQ® advanced hybrid closed-loop technology, demonstrating statistically significant improvements in glycemic and patient-reported outcomes. Emphasis was placed on qualitative experiences as well as insights from diverse populations using the system. The data was presented this week during the 81st Scientific Sessions of the American Diabetes Association.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 05,2021

The Accuracy of Continuous Glucose Monitoring in the Medical Intensive Care Unit

A Medtronic Enlite® sensor accuracy was assessed versus capillary blood glucose (CBG) and plasma glucose (PG) using the mean absolute relative difference (MARD), surveillance error grid (SEG) analysis and modified Bland-Altman plots.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 05,2021

Trends in U.S. Insulin Use and Glucose Monitoring for People with Diabetes: 2009-2018

The IBM® MarketScan® Commercial and Medicare databases were used to identify trends in insulin use over 10 years. The study included people with T1D or T2D who filled a prescription for insulin in any calendar year from 2009 to 2018. The analyses examined insulin regimen and delivery and the use of glucose monitoring systems. Generalized estimating equations were used to test whether trends were statistically significant.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 20,2021

ASCENSIA DIABETES CARE LAUNCHES PATIENT ASSISTANCE PROGRAM TO PROVIDE BROADER ACCESS TO EVERSENSE CONTINUOUS GLUCOSE MONITORING SYSTEM

Under the Program, which is available immediately, eligible patients starting or continuing with the Eversense CGM System will need to pay the first $100 of their out-of-pocket costs. Ascensia will then cover up to $300 of the remaining balance for each 90-day sensor. Any additional costs will be the system user’s responsibility. Overall, the Program has the potential to save eligible Eversense users up to $1,200 per year on their cumulative 90-day sensor out-of-pocket costs.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM